Orally delivered decitabine loaded PLGA nanoparticles combined with docetaxel supress solid tumours: An in vitro investigation

Prateek Jain, Mradul Tiwari, Nitesh Kumar, J. Venkata Rao, N. Udupa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Docetaxel is one of the greatest chemotherapeutic agent used in the treatment of solid tumours. However, resistance to docetaxel is a major clinical issue, which obstacle to achieve long time survival for patients with advanced disease. The inherent presence or emergence of drug-resistant tumour clones confines its efficiency in the treatment of cancers. The understanding that epigenetic changes are prevalent in cancer and play a causative role in its biology has led to the development of new therapeutic approaches that target the epigenetic machinery. Exploiting the gene reactivation by using epigenetically acting agents in combination with cytotoxic therapies, is a strategy of huge clinical relevance. Decitabine (DEC) is one such epigenetic drug, but its major disadvantage is its low oral bioavailability. There is no oral dosage form available for DEC. Since PLGA has an advantage of overcoming acidic and enzymatic degradation, the present investigation was aimed at fabricating PLGA 50:50 nanoparticles of decitabine (DEC-NPs); and thereafter, examine a combination treatment in vitro and in vivo with docetaxel (DTX). DEC-NPs were formulated by spontaneous emulsification solvent diffusion technique. The optimized formulation had PS of 124.3 ± 4.2 nm, ZP of -23.2 ± 1.2 mV, and EE of 41.8 ± 4.3%. A comparative study indicated that the cytotoxicity of DTX and DEC combination on MCF-7 cells was significantly higher (p < 0.05) than DTX and DEC alone.

Original languageEnglish
Pages (from-to)417-424
Number of pages8
JournalResearch Journal of Pharmaceutical, Biological and Chemical Sciences
Volume7
Issue number5
Publication statusPublished - 01-09-2016

Fingerprint

decitabine
docetaxel
Nanoparticles
Tumors
Neoplasms
Epigenomics
Therapeutics
Emulsification
MCF-7 Cells
Dosage Forms
Cytotoxicity
In Vitro Techniques
polylactic acid-polyglycolic acid copolymer
Pharmaceutical Preparations
Biological Availability
Machinery

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{38828e79409647e6b867a72d888bff06,
title = "Orally delivered decitabine loaded PLGA nanoparticles combined with docetaxel supress solid tumours: An in vitro investigation",
abstract = "Docetaxel is one of the greatest chemotherapeutic agent used in the treatment of solid tumours. However, resistance to docetaxel is a major clinical issue, which obstacle to achieve long time survival for patients with advanced disease. The inherent presence or emergence of drug-resistant tumour clones confines its efficiency in the treatment of cancers. The understanding that epigenetic changes are prevalent in cancer and play a causative role in its biology has led to the development of new therapeutic approaches that target the epigenetic machinery. Exploiting the gene reactivation by using epigenetically acting agents in combination with cytotoxic therapies, is a strategy of huge clinical relevance. Decitabine (DEC) is one such epigenetic drug, but its major disadvantage is its low oral bioavailability. There is no oral dosage form available for DEC. Since PLGA has an advantage of overcoming acidic and enzymatic degradation, the present investigation was aimed at fabricating PLGA 50:50 nanoparticles of decitabine (DEC-NPs); and thereafter, examine a combination treatment in vitro and in vivo with docetaxel (DTX). DEC-NPs were formulated by spontaneous emulsification solvent diffusion technique. The optimized formulation had PS of 124.3 ± 4.2 nm, ZP of -23.2 ± 1.2 mV, and EE of 41.8 ± 4.3{\%}. A comparative study indicated that the cytotoxicity of DTX and DEC combination on MCF-7 cells was significantly higher (p < 0.05) than DTX and DEC alone.",
author = "Prateek Jain and Mradul Tiwari and Nitesh Kumar and {Venkata Rao}, J. and N. Udupa",
year = "2016",
month = "9",
day = "1",
language = "English",
volume = "7",
pages = "417--424",
journal = "Research Journal of Pharmaceutical, Biological and Chemical Sciences",
issn = "0975-8585",
publisher = "RJPBCS",
number = "5",

}

TY - JOUR

T1 - Orally delivered decitabine loaded PLGA nanoparticles combined with docetaxel supress solid tumours

T2 - An in vitro investigation

AU - Jain, Prateek

AU - Tiwari, Mradul

AU - Kumar, Nitesh

AU - Venkata Rao, J.

AU - Udupa, N.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Docetaxel is one of the greatest chemotherapeutic agent used in the treatment of solid tumours. However, resistance to docetaxel is a major clinical issue, which obstacle to achieve long time survival for patients with advanced disease. The inherent presence or emergence of drug-resistant tumour clones confines its efficiency in the treatment of cancers. The understanding that epigenetic changes are prevalent in cancer and play a causative role in its biology has led to the development of new therapeutic approaches that target the epigenetic machinery. Exploiting the gene reactivation by using epigenetically acting agents in combination with cytotoxic therapies, is a strategy of huge clinical relevance. Decitabine (DEC) is one such epigenetic drug, but its major disadvantage is its low oral bioavailability. There is no oral dosage form available for DEC. Since PLGA has an advantage of overcoming acidic and enzymatic degradation, the present investigation was aimed at fabricating PLGA 50:50 nanoparticles of decitabine (DEC-NPs); and thereafter, examine a combination treatment in vitro and in vivo with docetaxel (DTX). DEC-NPs were formulated by spontaneous emulsification solvent diffusion technique. The optimized formulation had PS of 124.3 ± 4.2 nm, ZP of -23.2 ± 1.2 mV, and EE of 41.8 ± 4.3%. A comparative study indicated that the cytotoxicity of DTX and DEC combination on MCF-7 cells was significantly higher (p < 0.05) than DTX and DEC alone.

AB - Docetaxel is one of the greatest chemotherapeutic agent used in the treatment of solid tumours. However, resistance to docetaxel is a major clinical issue, which obstacle to achieve long time survival for patients with advanced disease. The inherent presence or emergence of drug-resistant tumour clones confines its efficiency in the treatment of cancers. The understanding that epigenetic changes are prevalent in cancer and play a causative role in its biology has led to the development of new therapeutic approaches that target the epigenetic machinery. Exploiting the gene reactivation by using epigenetically acting agents in combination with cytotoxic therapies, is a strategy of huge clinical relevance. Decitabine (DEC) is one such epigenetic drug, but its major disadvantage is its low oral bioavailability. There is no oral dosage form available for DEC. Since PLGA has an advantage of overcoming acidic and enzymatic degradation, the present investigation was aimed at fabricating PLGA 50:50 nanoparticles of decitabine (DEC-NPs); and thereafter, examine a combination treatment in vitro and in vivo with docetaxel (DTX). DEC-NPs were formulated by spontaneous emulsification solvent diffusion technique. The optimized formulation had PS of 124.3 ± 4.2 nm, ZP of -23.2 ± 1.2 mV, and EE of 41.8 ± 4.3%. A comparative study indicated that the cytotoxicity of DTX and DEC combination on MCF-7 cells was significantly higher (p < 0.05) than DTX and DEC alone.

UR - http://www.scopus.com/inward/record.url?scp=84987749257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987749257&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84987749257

VL - 7

SP - 417

EP - 424

JO - Research Journal of Pharmaceutical, Biological and Chemical Sciences

JF - Research Journal of Pharmaceutical, Biological and Chemical Sciences

SN - 0975-8585

IS - 5

ER -